Osmotica Receives FDA Approval for Droopy Eyelid Treatment
Osmotica Pharmaceuticals Plc (OSMT) reported that the FDA has given its approval for the company’s novel treatment for acquired blepharoptosis, or ptosis. Upneeq is now the only FDA-approved medical treatment for acquired blepharoptosis. One study involving adults over the age of 50 indicated that close to 11 percent of adults suffer from this condition.
Osmotica is looking to launch the flagship product in the market by next month. It will be available to an exclusive group of ophthalmologists and optometrists through an early experience program.